* Inari Medical Inc NARI.OQ NARI.O is expected to show a
rise
in quarterly revenue when it reports results on November 2.
* The Irvine California-based company is expected to report
a
24.0% increase in revenue to $90.402 million from $72.92 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Inari Medical Inc
is for
a loss of 25 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Inari
Medical Inc
is $94, above its last closing price of $76.93.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.23 -0.23 -0.19 Beat 17.4
Mar. 31 2022 -0.09 -0.09 -0.06 Beat 34.5
Dec. 31 2021 0.06 0.03 0.02 Missed -23.1
Sep. 30 2021 -0.21 -0.11 -0.06 Beat 45.5
Jun. 0.09 0.08 0.07 Missed -14.3
30 2021
Mar. 31 2021 0.07 0.05 0.13 Beat 151.6
Dec. 31 2020 0.02 0.01 0.13 Beat 875.2
Sep. 30 2020 -0.03 -0.04 0.12 Beat 415.8
This summary was machine generated November 1 at 02:06 GMT. All
figures in US dollars unless otherwise stated